The federal government (the FDA and DEA) move slowly on approving new drugs — it takes 2+ years minimum, usually longer. Congress is gridlocked and doesn't move fast on drug policy. But individual states can act quickly. Oregon, Colorado, and especially California have bills moving through their legislatures right now to let people access psychedelics like psilocybin and MDMA under controlled, supervised conditions. It's very likely that at least one major state — probably California — will pass and implement a regulated psychedelic access framework before the FDA approves any psychedelic as medicine or before Congress changes federal drug law. This matters because it creates a real-world proof-of-concept that voters and other states will copy.
Federal action on psychedelics faces DEA scheduling constraints, congressional gridlock, and FDA approval timelines of 2+ years minimum. State-level momentum (Oregon, Colorado active; California pending) is empirically the faster path. California's legislative capacity and population make it the most likely national model. The resolve date was originally listed as 2026-08-12 which is inconsistent with a 2026-2027 claim; extended to 2027-12-31 for coherence. One dissenting agent (dea_officer) noted federal preemption risk, which is real but unlikely to materialize within this window.